Cargando…

High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses

The viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly its cell-binding spike protein gene, has undergone rapid evolution during the coronavirus disease 2019 (COVID-19) pandemic. Variants including Omicron BA.1 and Omicron BA.2 now seriously threaten the effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sims, Joshua J., Lian, Sharon, Meggersee, Rosemary L., Kasimsetty, Aradhana, Wilson, James M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409550/ https://www.ncbi.nlm.nih.gov/pubmed/36006993 http://dx.doi.org/10.1371/journal.pone.0271359

Ejemplares similares

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
por: Zhang, Lianghui, et al.
Publicado: (2022)

An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
por: Tanaka, Shiho, et al.
Publicado: (2021)

Computationally engineered ACE2 decoy binds with nanomolar affinity with the SARS-CoV-2 spike protein
por: Islam, Mohammad S., et al.
Publicado: (2022)

Machine learning guided design of high affinity ACE2 decoys for SARS-CoV-2 neutralization
por: Chan, Matthew C., et al.
Publicado: (2021)

An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant
por: Zhang, Haoran, et al.
Publicado: (2022)

An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo
por: Ikemura, Nariko, et al.
Publicado: (2022)

Engineering ACE2 decoy receptors to combat viral escapability
por: Arimori, Takao, et al.
Publicado: (2022)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
por: Huo, Jiandong, et al.
Publicado: (2023)

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
por: Moulana, Alief, et al.
Publicado: (2022)

Outsmarting SARS-CoV-2 by empowering a decoy ACE2
por: Sokolowska, Milena
Publicado: (2020)

A decoy mutant ACE2 designed to reduce COVID-19
por: Maishan, Mazharul, et al.
Publicado: (2022)

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
por: Zhang, Lianghui, et al.
Publicado: (2022)

A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo
por: Havranek, Brandon, et al.
Publicado: (2023)

Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2
por: Philip, Angelin M., et al.
Publicado: (2023)

Drug screening and development from the affinity of S protein of new coronavirus with ACE2
por: Jiang, Yue-Peng, et al.
Publicado: (2020)

ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection
por: Ching, Krystal L., et al.
Publicado: (2022)

Cellular decoys distract coronavirus
por: Bradley, David
Publicado: (2020)

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

Binding affinity improvement analysis of multiple-mutant Omicron on 2019-nCov to human ACE2 by in silico predictions
por: Li, Bo, et al.
Publicado: (2023)

Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis
por: Ortega, Joseph Thomas, et al.
Publicado: (2021)

Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
por: Sims, Joshua J., et al.
Publicado: (2021)

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
por: Linsky, Thomas W., et al.
Publicado: (2020)

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
por: Zhang, Lianghui, et al.
Publicado: (2022)

SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
por: Wu, Leyun, et al.
Publicado: (2022)

Generation of enzymatically competent SARS‐CoV‐2 decoy receptor ACE2‐Fc in glycoengineered Nicotiana benthamiana
por: Castilho, Alexandra, et al.
Publicado: (2021)

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
por: Capraz, Tümay, et al.
Publicado: (2021)

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
por: Kegler, Alexandra, et al.
Publicado: (2023)

Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection
por: Lu, Mengjia, et al.
Publicado: (2023)

Omicron Coronavirus: pH-Dependent Electrostatic Potential and Energy of Association of Spike Protein to ACE2 Receptor
por: Hristova, Svetlana H., et al.
Publicado: (2023)

Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding
por: Lin, Sheng, et al.
Publicado: (2022)

Scanning the RBD-ACE2 molecular interactions in Omicron variant
por: Rath, Soumya Lipsa, et al.
Publicado: (2022)

Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants
por: Sang, Peng, et al.
Publicado: (2022)

CSAR Data Set Release 2012: Ligands, Affinities, Complexes, and Docking Decoys
por: Dunbar, James B., et al.
Publicado: (2013)

Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants
por: Tang, Haoneng, et al.
Publicado: (2022)

Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1
por: Li, Linjie, et al.
Publicado: (2022)

Omicron: Master of immune evasion maintains robust ACE2 binding
por: Hoffmann, Markus, et al.
Publicado: (2022)

Computational redesign of Beta-27 Fab with substantially better predicted binding affinity to the SARS-CoV-2 Omicron variant than human ACE2 receptor
por: Treewattanawong, Wantanee, et al.
Publicado: (2023)

Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
por: Klaassen, Fayette, et al.
Publicado: (2022)

Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
por: Inal, Jameel M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n8eomqeuq70ads8bcij0fp3s09